HK Stock Market Move | HENLIUS (02696) further increased by over 6% granting Sandoz AG the rights to develop, produce, and commercialize product HLX13.

HENLIUS (02696) rose more than 6%, up 6.46% to 40.35 Hong Kong dollars with a turnover of 27.3043 million Hong Kong dollars as of the time of writing. On the news side, HENLIUS announced at the end of April that it granted Sandoz AG the rights to develop, manufacture, and commercialize its investigational product HLX13 (a recombinant anti-CTLA-4 human monoclonal antibody injection) in the licensed territory and field. Sandoz AG will pay up to 191 million US dollars to HENLIUS for the licensed product, including an upfront payment of 31 million US dollars and development milestone payments. Tianfeng believes that with the good commercialization capabilities of Sandoz and the company's leading global clinical progress, HLX13 is expected to drive further expansion of the company's overall sales peak for similar drugs overseas. The bank previously pointed out that considering the company's innovation pipeline and overseas layout are expected to enter a harvest period: the differentiated PD-1 Schruli monoclonal antibody in the innovative drug sector has significant efficacy advantages in the indications of small cell lung cancer, and the subsequent commercialization potential in other indications is worth looking forward to; the clinical data for HLX22 is excellent, with the potential to become 1st line HER+ gastric cancer standard of care; PD-L1ADC has a large market space and potential BIC value; biosimilars and innovative drugs going overseas are expected to land intensively by 2025, and the company's development prospects are promising.